Effect of prostaglandin synthetase inhibitors on pressor response to angiotensin II in human pregnancy

R. B. Everett, R. J. Worley, P. C. MacDonald, N. F. Gant

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Pregnant women destined to develop pregnancy-induced hypertension (PIH) lose refractoriness to the pressor effects of infused angiotensin II (A-II) several weeks before the onset of hypertension. This loss of refractoriness to A-II is unrelated to plasma renin activity or circulating levels of A-II. In animal studies it has been shown that the prostaglandins are important mediators of vascular reactivity. Specifically, the uterine blood flow appears to vary directly with prostaglandin E concentrations in uterine venous effluent. The present study was designed to evaluate the effects of prostaglandin synthetase inhibitors on the pressor effects of A-II in human pregnancy. The 'effective A-II pressor dose' (nanograms of A-II/kg/min of A-II kg -1.min -1 necessary to cause a 20 mm Hg rise in diastolic pressure) was determined in 14 pregnant women before and after treatment with either 25 mg indomethacin or 600 mg aspirin given twice, 6 h apart. The effective pressor dose required before treatment [22.7±3.4 ng/kg (mean ± SE)] was significantly greater than that after treatment [8.7 ± 1.2 ng/kg/min (P<0.001)]. The refractoriness to A-II observed in normal human pregnancy may be mediated in part by the action of prostaglandins or related substances produced in the arteriole.

Original languageEnglish (US)
Pages (from-to)1007-1010
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume46
Issue number6
StatePublished - 1978

Fingerprint

Prostaglandin Antagonists
Prostaglandin-Endoperoxide Synthases
Angiotensin II
Pregnancy
Prostaglandins
Pregnant Women
Pregnancy Induced Hypertension
Arterioles
Prostaglandins E
Renin
Indomethacin
Aspirin
Blood Vessels
Effluents
Animals
Blood
Therapeutics
Blood Pressure
Hypertension
Plasmas

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of prostaglandin synthetase inhibitors on pressor response to angiotensin II in human pregnancy. / Everett, R. B.; Worley, R. J.; MacDonald, P. C.; Gant, N. F.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 46, No. 6, 1978, p. 1007-1010.

Research output: Contribution to journalArticle

Everett, R. B. ; Worley, R. J. ; MacDonald, P. C. ; Gant, N. F. / Effect of prostaglandin synthetase inhibitors on pressor response to angiotensin II in human pregnancy. In: Journal of Clinical Endocrinology and Metabolism. 1978 ; Vol. 46, No. 6. pp. 1007-1010.
@article{762c1c4d7a8c4cb8ae8af5c237769794,
title = "Effect of prostaglandin synthetase inhibitors on pressor response to angiotensin II in human pregnancy",
abstract = "Pregnant women destined to develop pregnancy-induced hypertension (PIH) lose refractoriness to the pressor effects of infused angiotensin II (A-II) several weeks before the onset of hypertension. This loss of refractoriness to A-II is unrelated to plasma renin activity or circulating levels of A-II. In animal studies it has been shown that the prostaglandins are important mediators of vascular reactivity. Specifically, the uterine blood flow appears to vary directly with prostaglandin E concentrations in uterine venous effluent. The present study was designed to evaluate the effects of prostaglandin synthetase inhibitors on the pressor effects of A-II in human pregnancy. The 'effective A-II pressor dose' (nanograms of A-II/kg/min of A-II kg -1.min -1 necessary to cause a 20 mm Hg rise in diastolic pressure) was determined in 14 pregnant women before and after treatment with either 25 mg indomethacin or 600 mg aspirin given twice, 6 h apart. The effective pressor dose required before treatment [22.7±3.4 ng/kg (mean ± SE)] was significantly greater than that after treatment [8.7 ± 1.2 ng/kg/min (P<0.001)]. The refractoriness to A-II observed in normal human pregnancy may be mediated in part by the action of prostaglandins or related substances produced in the arteriole.",
author = "Everett, {R. B.} and Worley, {R. J.} and MacDonald, {P. C.} and Gant, {N. F.}",
year = "1978",
language = "English (US)",
volume = "46",
pages = "1007--1010",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Effect of prostaglandin synthetase inhibitors on pressor response to angiotensin II in human pregnancy

AU - Everett, R. B.

AU - Worley, R. J.

AU - MacDonald, P. C.

AU - Gant, N. F.

PY - 1978

Y1 - 1978

N2 - Pregnant women destined to develop pregnancy-induced hypertension (PIH) lose refractoriness to the pressor effects of infused angiotensin II (A-II) several weeks before the onset of hypertension. This loss of refractoriness to A-II is unrelated to plasma renin activity or circulating levels of A-II. In animal studies it has been shown that the prostaglandins are important mediators of vascular reactivity. Specifically, the uterine blood flow appears to vary directly with prostaglandin E concentrations in uterine venous effluent. The present study was designed to evaluate the effects of prostaglandin synthetase inhibitors on the pressor effects of A-II in human pregnancy. The 'effective A-II pressor dose' (nanograms of A-II/kg/min of A-II kg -1.min -1 necessary to cause a 20 mm Hg rise in diastolic pressure) was determined in 14 pregnant women before and after treatment with either 25 mg indomethacin or 600 mg aspirin given twice, 6 h apart. The effective pressor dose required before treatment [22.7±3.4 ng/kg (mean ± SE)] was significantly greater than that after treatment [8.7 ± 1.2 ng/kg/min (P<0.001)]. The refractoriness to A-II observed in normal human pregnancy may be mediated in part by the action of prostaglandins or related substances produced in the arteriole.

AB - Pregnant women destined to develop pregnancy-induced hypertension (PIH) lose refractoriness to the pressor effects of infused angiotensin II (A-II) several weeks before the onset of hypertension. This loss of refractoriness to A-II is unrelated to plasma renin activity or circulating levels of A-II. In animal studies it has been shown that the prostaglandins are important mediators of vascular reactivity. Specifically, the uterine blood flow appears to vary directly with prostaglandin E concentrations in uterine venous effluent. The present study was designed to evaluate the effects of prostaglandin synthetase inhibitors on the pressor effects of A-II in human pregnancy. The 'effective A-II pressor dose' (nanograms of A-II/kg/min of A-II kg -1.min -1 necessary to cause a 20 mm Hg rise in diastolic pressure) was determined in 14 pregnant women before and after treatment with either 25 mg indomethacin or 600 mg aspirin given twice, 6 h apart. The effective pressor dose required before treatment [22.7±3.4 ng/kg (mean ± SE)] was significantly greater than that after treatment [8.7 ± 1.2 ng/kg/min (P<0.001)]. The refractoriness to A-II observed in normal human pregnancy may be mediated in part by the action of prostaglandins or related substances produced in the arteriole.

UR - http://www.scopus.com/inward/record.url?scp=0018141909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018141909&partnerID=8YFLogxK

M3 - Article

C2 - 122438

AN - SCOPUS:0018141909

VL - 46

SP - 1007

EP - 1010

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -